Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients

Journal of Alzheimer's Disease

Volumn 23, Issue 2, 2011, Pages 319-326

  Rami, Lorena ^a   Fortea, Juan ^a   Bosch, Beatriz ^a   Solé Padullés, Cristina ^a   Lladó, Albert ^a,b   Iranzo, Alex ^a,b   Sánchez Valle, Raquel ^a,b   Molinuevo, Jose Luis ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer's disease; amyloid; cerebrospinal fluid; cognition; neuropsychological tests

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; P TAU PROTEIN; T TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BOSTON NAMING TEST; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DEMENTIA RATING; COGNITION; CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMER DISEASE BATTERY; CONSTRUCTIVE PRAXIS TEST; CONTROLLED STUDY; COWAT; DEMENTIA; DISEASE ASSOCIATION; FINGER SPAN; FREE AND CUED SELECTIVE REMINDING TEST; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MEMORY ALTERATION TEST; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; PERCEPTUAL DIGITAL TEST; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RECALL; SEMANTIC MEMORY; SUBJECTIVE MEMORY COMPLAINT; WORD LIST RECALL;

EID: 79951568317     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101422     Document Type: Article

References (41)

1. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
2. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
3. Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
4. Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg 107, 65-73.
5. 1-42 and increased tau levels in cereb (Pubitemid 37430211)
6. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234. (Pubitemid 43238346)
7. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet 6, 734-746. (Pubitemid 47058377)
8. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley- Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931. (Pubitemid 38435780)
9. Jack CR, Knopman DS, Jagust WJ, Leslie MS, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
10. Wallin AK, BlennowK, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer's disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21, 131-138. (Pubitemid 43201321)
11. 1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44, 192-195. (Pubitemid 43237964)
12. Lin YT, Cheng JT, Yao YC, Juo, Lo YK, Lin CH, Ger LP, Lu PJ (2009) Increased total TAU but not amyloid-beta (42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease. J Alzheimers Dis 18, 907-918.
13. 1-42 but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J Alzheimers Dis 16, 157-165.
14. 42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 11, 32-39. (Pubitemid 40372858)
15. Amieva H, Jacqmin-Gadda H, Orgogozo M, Le Carret N, Helmer C, Letenneur L, Barberger-Gateau P, Fabrigoule C, Dartigues JF (2005) The 9 year cognitive decline before dementia of Alzheimer type: a prospective population-based study. Brain 128(pt 5), 1093-1101. (Pubitemid 40675464)
16. Nestor PJ, Scheltens P, Hodges JR (2004) Advances in the early detection of Alzheimer's disease. Nat Med 10(suppl), S34-S41. (Pubitemid 38901865)
17. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992. (Pubitemid 33143977)
18. Grober E, Buschke H (1987) Genuine memory deficits in dementia. Dev Neuropsychol 3, 13-36.
19. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S (1982) Measurement of functional activities in older adults in the community. J Gerontol 37, 323-329. (Pubitemid 12117513)
20. Rami L, Serradell B, Bosch B, Villar A, Molinuevo JL (2007) Valores normativos de test de función cognitiva frontal para la población mayor de 60 años. Rev Neurol 45, 268-271. (Pubitemid 350292947)
21. Rami L, Serradell M, Bosch B, Caprile C, Sekler A, Villar A, Canal R, Molinuevo JL (2008) Semantic memory tests in the Spanish Elderly. Normative data for the Boston Naming Test and for the Pyramids and Palm trees test. J Clin Exp Neuropsychol 30, 1-6.
22. Rami L, Serradell M, Bosch B, Villar A, Molinuevo JL (2007) Test digital de percepción (TDP) para la valoración de trastornos perceptivos incipientes en la Enfermedad de Alzheimer inicial. Neurologia 22, 342-347. (Pubitemid 47123004)
23. Folstein MF, Folstein SE, McHugh PR; Mini-mental state (1975) A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
24. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165. (Pubitemid 19239715)
25. Garcia-Albea JE, Sanchez-Bernardos ML, del Viso-Pabon S (1986) Test de Boston para el diagnóstico de la afasia: Adaptación española. In La evaluación de la afasia y de trastornos relacionados, Goodglass H, Kaplan E, eds. 2nd ed. Translated by Carlos Wernicke. Editorial Medica Panamericana, Madrid. pp. 129-198.
26. Borkowski JG, Benton AL, Spreen O (1967) Word fluency and brain damage. Neuropsychologia 5, 135-140.
27. Reitan RM (1958) Validity of the Trail Making test as an indicator of organic brain damage. Percep Mot Skills 8, 271-276.
28. Wechsler D (1999) Escala de inteligencia de Wechsler para adultos-III (WAIS III), TEA. Madrid.
29. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P (2004) Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 62, 1580-1584. (Pubitemid 38608199)
30. Schoonenboom SN, Visser PJ, Mulder C, Lindeboom J, Van Elk EJ, Van Kamp GJ, Scheltens PH (2005)Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 11, 8-13. (Pubitemid 40372855)
31. 42. Int Psychogeriatr 22, 598-606.
32. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr (2010) Alzheimer's Disease Neuroimaging Initiative. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316.
33. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
34. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24, 118-124. (Pubitemid 47094071)
35. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O'Keefe GJ, Salvado O, Masters CL, Rowe CC (2010) Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 67, 317-324.
36. Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A (2008) Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropsychol Soc 14, 582-590. (Pubitemid 351935880)
37. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL (2008) Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92.
38. 42 levels precede cognitive decline. Neurology 65, 323-325. (Pubitemid 41022387)
39. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65, 176-183.
40. Guillozet AL, Weintraub S, Mash DC, Mesulam MM (2003) Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol 60, 729-736. (Pubitemid 36569891)
41. Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY, Bienias JL, Lee VM, Trojanowski JQ, Bennett DA, Arnold SE (2002) Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 51, 182-189. (Pubitemid 34111440)